Cyclerion Therapeutics, Inc. (CYCN)
- Previous Close
2.8500 - Open
2.9000 - Bid 2.1600 x 200
- Ask 3.7500 x 200
- Day's Range
2.9000 - 3.1006 - 52 Week Range
1.2700 - 9.4700 - Volume
7,495 - Avg. Volume
33,293 - Market Cap (intraday)
9.305M - Beta (5Y Monthly) 1.67
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1500 - Earnings Date Aug 5, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
www.cyclerion.comRecent News: CYCN
View MorePerformance Overview: CYCN
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CYCN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CYCN
View MoreValuation Measures
Market Cap
9.31M
Enterprise Value
5.67M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.70
Price/Book (mrq)
1.06
Enterprise Value/Revenue
2.72
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-141.47%
Return on Assets (ttm)
-20.43%
Return on Equity (ttm)
-31.48%
Revenue (ttm)
2.08M
Net Income Avi to Common (ttm)
-2.94M
Diluted EPS (ttm)
-1.1500
Balance Sheet and Cash Flow
Total Cash (mrq)
3.64M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.52M